DOCSLIB.ORG

Redox-Mediated Regulation of the Tyrosine Kinase Zap70

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Redox-Mediated Regulation of the Tyrosine Kinase Zap70 Redox-mediated regulation of the tyrosine kinase Zap70 DISSERTATION zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) genehmigt durch die Fakultät für Naturwissenschaften der Otto-von-Guericke-Universität von M.Sc. Christoph Thurm geb. am 27.06.1988 in Borna Gutachter: apl. Prof. Dr. Luca Simeoni PD Dr. rer. nat. Marcus Lettau eingereicht am: 02.02.2018 verteidigt am: 06.06.2018 Eigenständigkeitserklärung I. Eigenständigkeitserklärung Christoph Thurm Halberstädter Straße 29 39112 Magdeburg Hiermit erkläre ich, dass ich die von mir eingereichte Dissertation zu dem Thema Redox-mediated regulation of the tyrosine kinase Zap70 selbständig verfasst, nicht schon als Dissertation verwendet habe und die benutzten Hilfsmittel und Quellen vollständig angegeben wurden. Weiterhin erkläre ich, dass ich weder diese noch eine andere Arbeit zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) an anderen Einrichtungen eingereicht habe. Magdeburg, den 02.02.2018 ____________________________________ M.Sc. Christoph Thurm II ACKNOWLEDGEMENTS II. Acknowledgements Firstly, I would like to express my sincere gratitude to my supervisor Prof. Dr. Luca Simeoni. His extraordinary support during my PhD thesis together with his motivation and knowledge enabled me to pursue my dream. I could not have imagined having a better mentor. Furthermore, I would like to thank Prof. Dr. Burkhart Schraven for giving me the opportunity to work in his institute. His support, ideas, and the lively discussions promoted me to develop as a scientist. Special thanks go also to the whole AG Simeoni/Schraven - Ines, Camilla, Matthias, and Andreas - for the help with experiments, the discussions, and the fun we had. This helped to sustain also the longest days. Also, I would like to thank the whole IMKI team for the outstanding atmosphere and spirit. I really enjoyed being a part of you. I would like to thank my family and friends who covered my back also during the most painful times. Especially my father who guided me to become the person I am today. Finally, I would like to thank Anne who supported me every single day and blessed me with her patience and her positive attitude. Words cannot express what it means to me to know you by my side. III TABLE OF CONTENT III. Table of content I. EIGENSTÄNDIGKEITSERKLÄRUNG ........................................................................................... II II. ACKNOWLEDGEMENTS .............................................................................................................. III III. TABLE OF CONTENT ................................................................................................................... IV IV. LIST OF FIGURES AND TABLES ................................................................................................ VII V. ABBREVIATIONS .......................................................................................................................... IX VI. ABSTRACT ................................................................................................................................... XII VII. ZUSAMMENFASSUNG ............................................................................................................... XIII 1. INTRODUCTION ............................................................................................................................. 1 1.1 SIGNALING IN EUKARYOTIC CELLS .................................................................................................. 1 1.2 PROTEIN TYROSINE KINASES ......................................................................................................... 2 1.2.1 Receptor Tyrosine Kinases ............................................................................................. 4 1.2.2 Non-receptor tyrosine kinases ......................................................................................... 6 1.3 THE TYROSINE KINASE ZAP70 ........................................................................................................ 8 1.3.1 Function of Zap70 ............................................................................................................ 9 1.3.1.1 T cells and TCR signaling ......................................................................................................... 9 1.3.1.2 T-cell development .................................................................................................................. 11 1.3.2 Zap70 in diseases .......................................................................................................... 13 1.3.2.1 Immunodeficiency ................................................................................................................... 13 1.3.2.2 Autoimmunity .......................................................................................................................... 15 1.3.2.3 Leukemia ................................................................................................................................ 16 1.3.3 Regulation of Zap70 ...................................................................................................... 17 1.3.3.1 Membrane recruitment ............................................................................................................ 17 1.3.3.2 Tyrosine phosphorylation ........................................................................................................ 19 1.3.3.3 Ubiquitination .......................................................................................................................... 22 1.3.3.4 Oxidation ................................................................................................................................. 23 1.4 REGULATION OF TYROSINE KINASES BY OXIDATION ....................................................................... 24 1.4.1 Cellular sources of ROS and RNS ................................................................................ 26 1.4.2 Modulation of the activity of tyrosine kinases by oxidation ............................................ 29 1.4.2.1 Direct regulation of kinases via ROS....................................................................................... 29 1.4.2.2 Regulation of phosphatases by ROS ...................................................................................... 30 1.4.2.3 Perspectives in therapy ........................................................................................................... 30 1.5 AIMS OF THE STUDY .................................................................................................................... 32 2. MATERIALS AND METHODS ...................................................................................................... 33 2.1 CHEMICALS, ANTIBODIES, AND OTHER REAGENTS ......................................................................... 33 2.1.1 Chemicals ...................................................................................................................... 33 2.1.2 Antibodies for western blot and immunoprecipitation .................................................... 34 2.1.3 Antibodies for intracellular FACS analysis .................................................................... 34 2.1.4 Antibodies for stimulation .............................................................................................. 34 2.2 PLASMIDS ................................................................................................................................... 35 2.3 BUFFERS AND SOLUTIONS ............................................................................................................ 35 2.4 CELL CULTURE ............................................................................................................................ 38 2.4.1 Jurkat cell culture ........................................................................................................... 38 2.4.2 HEK293T cell culture ..................................................................................................... 38 2.4.3 Treatments with inhibitors and antioxidants .................................................................. 38 2.5 SITE DIRECTED MUTAGENESIS ...................................................................................................... 39 2.6 TRANSFECTION ........................................................................................................................... 41 2.6.1 Transfection by calcium phosphate ............................................................................... 41 2.6.2 Transfection by electroporation ..................................................................................... 42 2.7 CELL STIMULATION ...................................................................................................................... 42 2.7.1 Stimulation with soluble Antibodies (sAbs) .................................................................... 42 2.7.2 Ca2+-Flux measurements ............................................................................................... 42 2.7.3 Stimulation with antibodies immobilized on microspheres (iAbs) .................................. 42 IV TABLE OF CONTENT 2.8 WESTERN BLOTTING .................................................................................................................... 43 2.8.1 General procedure ........................................................................................................
Load more

Recommended publications
  • Stem Cell Factor Is Selectively Secreted by Arterial Endothelial Cells in Bone Marrow
    ARTICLE DOI: 10.1038/s41467-018-04726-3 OPEN Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow Chunliang Xu1,2, Xin Gao1,2, Qiaozhi Wei1,2, Fumio Nakahara 1,2, Samuel E. Zimmerman3,4, Jessica Mar3,4 & Paul S. Frenette 1,2,5 Endothelial cells (ECs) contribute to haematopoietic stem cell (HSC) maintenance in bone marrow, but the differential contributions of EC subtypes remain unknown, owing to the lack 1234567890():,; of methods to separate with high purity arterial endothelial cells (AECs) from sinusoidal endothelial cells (SECs). Here we show that the combination of podoplanin (PDPN) and Sca-1 expression distinguishes AECs (CD45− Ter119− Sca-1bright PDPN−) from SECs (CD45− Ter119− Sca-1dim PDPN+). PDPN can be substituted for antibodies against the adhesion molecules ICAM1 or E-selectin. Unexpectedly, prospective isolation reveals that AECs secrete nearly all detectable EC-derived stem cell factors (SCF). Genetic deletion of Scf in AECs, but not SECs, significantly reduced functional HSCs. Lineage-tracing analyses suggest that AECs and SECs self-regenerate independently after severe genotoxic insults, indicating the per- sistence of, and recovery from, radio-resistant pre-specified EC precursors. AEC-derived SCF also promotes HSC recovery after myeloablation. These results thus uncover heterogeneity in the contribution of ECs in stem cell niches. 1 The Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, New York, NY 10461, USA. 2 Department of Cell Biology, Albert Einstein College of Medicine, New York, NY 10461, USA. 3 Department of Systems and Computational Biology, Albert Einstein College of Medicine, New York, NY 10461, USA.
    [Show full text]
  • Survival Pathways That Regulate Macrophage Tec and Btk in M-CSF
    Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival This information is current as of September 26, 2021. Martin Melcher, Bernd Unger, Uwe Schmidt, Iiro A. Rajantie, Kari Alitalo and Wilfried Ellmeier J Immunol 2008; 180:8048-8056; ; doi: 10.4049/jimmunol.180.12.8048 http://www.jimmunol.org/content/180/12/8048 Downloaded from References This article cites 36 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/180/12/8048.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival1 Martin Melcher,2* Bernd Unger,2† Uwe Schmidt,3* Iiro A.
    [Show full text]
  • Non-Redundant Dual Functions of the ZAP70 Catalytic and Scaffolding
    ical C lin as C e Isakov, J Clinic Case Reports 2012, 2:6 f R o l e DOI: 10.4172/2165-7920.1000e113 a p n o r r t u s o J Journal of Clinical Case Reports ISSN: 2165-7920 Editorial Open Access ZAP70-Related SCID: Non-Redundant Dual Functions of the ZAP70 Catalytic and Scaffolding Regions Noah Isakov* The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and the Cancer Research Center, Ben Gurion University of the Negev, P.O.B. 653, Beer Sheva 84105, Israel Primary Severe Combined Immunodeficiency (SCID) is a form rearrangement of the actin cytoskeleton. These transient intracellular of heritable immunodeficiency, characterized by impaired adaptive signals permit the activation of selected transcription factors that immune responses [1]. It includes a group of genetic disorders promote the proliferation and differentiation of T cells. originated by defects in one of several different genes that are critical Analysis of the phosphorylation sites of ZAP-70 and their impact for T lymphocyte production and/or function and involve defects in B on the function of the molecule demonstrated that phosphorylation lymphocytes as a primary or secondary cause [2]. of Tyr319, Tyr492 and Tyr493 serves to regulate the ZAP70 catalytic The most common type of SCID is linked to the X chromosome activity [23-25]. However, in vivo activation of T cells results in ZAP70 (X-SCID), and therefore affects only males [3,4]. The X-SCID males phosphorylation on additional tyrosine residues [26,27] which may possess mutations in the interleukin-2 (IL-2) receptor gamma chain also function as putative docking sites for SH2-containing proteins.
    [Show full text]
  • C-MET) Prolongs the Survival of Chronic Lymphocytic Leukemic Cells Through STAT3 Phosphorylation: a Potential Role of Mesenchymal Cells in the Disease
    SUPPLEMENTARY APPENDIX An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease Paolo Giannoni,1 Silvia Scaglione,2 Rodolfo Quarto,1,3 Roberto Narcisi,3 Manuela Parodi,1 Enrico Balleari,4 Federica Barbieri,5 Alessandra Pattarozzi,5 Tullio Florio,5 Silvano Ferrini,6 †Giorgio Corte,7 and Daniela de Totero7 1Stem Cell Laboratory, Advanced Biotechnology Center, 16132, Genova; 2Dept. of Communication, Computer and System Sciences (D.I.S.T.), University of Genova, 16132, Genova; 3Dept. of Experimental Medicine (Di.Me.S.), University of Genova, Genova; 4Hematological Dept., San Martino Hospital, 16132, Genova; 5Pharmacology Laboratory, Dept. of Oncology, Biology and Genetics (D.O.Bi.G.), University of Genova, 16132, Genova; 6Immunological Therapies Laboratory and 7Gene Transfer Laboratory, National Institute for Cancer Research, 16132, Genova, Italy Citation: Giannoni P, Scaglione S, Quarto R, Narcisi R, Parodi M, Balleari E, Barbieri F, Pattarozzi A, Florio T, Ferrini S, Corte G, and de Totero D. An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease. Haematologica 2011;96(7):1015- 1023. doi:10.3324/haematol.2010.029736 Online Supplementary Design and Methods ac.uk/microarray-as/ae/) and analyzed in silico with Bioconductor (open source Version 1.2.0; http://www.bioconductor.org/docs/faq/) Immunofluorescence analysis of cell surface antigen for background subtraction and normalization (series acces- expression on chronic lymphocytic leukemia cells sion numbers detailed in Online Supplementary Table S2).
    [Show full text]
  • Mechanisms of Topical Bruton Tyrosine Kinase Inhibitor PRN473 P1572 in Immune‑Mediated Models of Skin Disease Yan Xing, Katherine A
    E‑Poster Mechanisms of Topical Bruton Tyrosine Kinase Inhibitor PRN473 P1572 in Immune‑Mediated Models of Skin Disease Yan Xing, Katherine A. Chu, Jyoti Wadhwa, Wei Chen, Jiang Zhu, Jin Shu, Matthew C. Foulke, Natalie Loewenstein, Philip Nunn, Kolbot By, Pasit Phiasivongsa, David M. Goldstein, and Claire L. Langrish Principia Biopharma Inc, A Sanofi Company, South San Francisco, CA, USA • In vitro, PRN473 inhibited B‑cell activation and FcR signaling in monocytes and mast cells, and IgE‑Mediated PCA Mouse Reaction INTRODUCTION MATERIALS AND METHODS in the absence of cytotoxic effects and limited functional effects in basophils, epidermal growth factor receptor (EGFR), and cells absent BTK signaling (Table 1A) • Significant dose‑dependent inhibition of mouse PCA IgE‑mediated reaction was also observed with single and multiday • PRN473 demonstrated durable BTK inhibition at 4 h that was partially sustained through 18 h applications of PRN473 ≥1%, approaching positive controls with higher strengths up to 4% PRN473 (Figure 6) Bruton Tyrosine Kinase In Vitro Selectivity and Functional Assays (Table 1B) • Multiday (3 days) treatment achieved similar levels of inhibition with respect to single administration (data not shown) • Bruton tyrosine kinase (BTK) is a promising target in immunology because of its expression in • PRN473 1 µM was tested against a panel of 230 kinase targets in the KINOMEscan™ panel B cells and innate immune cells, providing essential downstream signaling for B‑cell receptors, Biochemical studies were performed to characterize the potency, selectivity, biochemical Table 1. Preclinical Target Specificity and BTK Occupancy for PRN473 Figure 6. Dose‑Dependent Inhibition in IgE Antibody‑Mediated Mouse Passive Fc receptors, and other innate cell pathways (Figure 1)1,2 • on‑rate and off‑rate, and reversibility of the interaction between PRN473 and BTK Cutaneous Anaphylaxis (PCA) With Single Application of PRN473 • Selective inhibition of BTK function and occupancy and off‑target effects were evaluated in A.
    [Show full text]
  • Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia
    Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia Title Page by Ravi K. Patel Bachelor of Science, University of Minnesota, 2013 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2019 Commi ttee Membership Pa UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE Commi ttee Membership Page This dissertation was presented by Ravi K. Patel It was defended on May 31, 2019 and approved by Qiming (Jane) Wang, Associate Professor Pharmacology and Chemical Biology Vaughn S. Cooper, Professor of Microbiology and Molecular Genetics Adrian Lee, Professor of Pharmacology and Chemical Biology Laura Stabile, Research Associate Professor of Pharmacology and Chemical Biology Thomas E. Smithgall, Dissertation Director, Professor and Chair of Microbiology and Molecular Genetics ii Copyright © by Ravi K. Patel 2019 iii Abstract Src-Family Kinases Play an Important Role in Flt3-ITD Acute Myeloid Leukemia Prognosis and Drug Efficacy Ravi K. Patel, PhD University of Pittsburgh, 2019 Abstract Acute myelogenous leukemia (AML) is a disease characterized by undifferentiated bone-marrow progenitor cells dominating the bone marrow. Currently the five-year survival rate for AML patients is 27.4 percent. Meanwhile the standard of care for most AML patients has not changed for nearly 50 years. We now know that AML is a genetically heterogeneous disease and therefore it is unlikely that all AML patients will respond to therapy the same way. Upregulation of protein-tyrosine kinase signaling pathways is one common feature of some AML tumors, offering opportunities for targeted therapy.
    [Show full text]
  • K-RAS Gtpase- and B-RAF Kinase–Mediated T-Cell PNAS PLUS Tolerance Defects in Rheumatoid Arthritis
    K-RAS GTPase- and B-RAF kinase–mediated T-cell PNAS PLUS tolerance defects in rheumatoid arthritis Karnail Singha,1, Pratima Deshpandeb,1, Guangjin Lib, Mingcan Yub, Sergey Pryshchepa, Mary Cavanaghb, Cornelia M. Weyandb, and Jörg J. Goronzyb,2 aLowance Center for Human Immunology and Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322; and bDepartment of Medicine, Stanford University School of Medicine and Palo Alto Department of Veterans Affairs Health Care System, Palo Alto, CA 94304 Edited by Dennis A. Carson, University of California at San Diego, La Jolla, CA, and approved April 18, 2012 (received for review November 3, 2011) Autoantibodies to common autoantigens and neoantigens, such the signaling cascade after T-cell receptor (TCR) stimulation. as IgG Fc and citrullinated peptides, are immunological hallmarks Based on the substitution conferring increased phosphatase ac- of rheumatoid arthritis (RA). We examined whether a failure in tivity, it was originally considered a gain of function (12). Recent maintaining tolerance is mediated by defects in T-cell receptor findings, however, have shown that the variant is rapidly de- activation threshold settings. RA T cells responded to stimulation graded, causing T-cell hyperresponsiveness (13). The findings with significantly higher ERK phosphorylation (P < 0.001). Gene of disease-associated HLA-DRB1 alleles and PTPN22 poly- expression arrays of ERK pathway members suggested a higher morphisms indicate that T-cell recognition events and TCR expression of KRAS and BRAF, which was confirmed by quantita- threshold calibration are central to RA pathogenesis (13, 14). tive PCR (P = 0.003), Western blot, and flow cytometry (P < 0.01).
    [Show full text]
  • Current Understanding of Tyrosine Kinase BMX in Inflammation and Its
    Burns & Trauma, July 2014, Vol 2, Issue 3 Review Article Current understanding of tyrosine kinase BMX in infl ammation and its inhibitors Le Qiu, Fei Wang, Sheng Liu, Xu-Lin Chen Department of Burns, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China Corresponding author: Xu-Lin Chen, Department of Burns, First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, Anhui 230022, China. E-mail: [email protected] Received: 14-04-14, Revised: 05-06-14, Accepted: 11-06-14 ABSTRACT Tec family kinases, which include tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton's tyrosine kinase (BTK), interleukin (IL)-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TXK), and bone marrow tyrosine kinase on chromosome X (BMX), are the second largest group of non-receptor tyrosine kinases and have a highly conserved carboxyl-terminal kinase domain. BMX was identifi ed in human bone marrow cells, and was demonstrated to have been expressed in myeloid hematopoietic lineages cells, endothelial cells, and several types of cancers. Signifi cant progress in this area during the last decade revealed an important role for BMX in infl ammation and oncologic disorders. This review focuses on BMX biology, its role in infl ammation and possible signaling pathways, and the potential of selective BMX inhibitors. Key words: BMX, infl ammation, tyrosine kinase Introduction tyrosine kinase on chromosome X (BMX).[2] Tec family kinases have been the focus of immunological interest ever The response of cells to extracellular stimuli is in part medi- since their discovery. ated by a number of intracellular kinases.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Review Bruton's Tyrosine Kinase Is Involved in Innate and Adaptive
    Histol Histopathol (2005) 20: 945-955 Histology and http://www.hh.um.es Histopathology Cellular and Molecular Biology Review Bruton’s Tyrosine Kinase is involved in innate and adaptive immunity C. Brunner, B. Müller and T. Wirth University of Ulm, Department of Physiological Chemistry, Ulm, Germany Summary. Btk is a cytoplasmic tyrosine kinase, which Btk is not restricted to B cells, it is also expressed in is mainly involved in B cell receptor signalling. Gene myeloid cells, like mast cells (Kawakami et al., 1994; targeting experiments revealed that Btk is important for Smith et al., 1994), monocytes/macrophages (de Weers B cell development and function. However, Btk is not et al., 1993; Smith et al., 1994), neutrophiles (Lachance only expressed in B cells, but also in most other et al., 2002), dendritic cells (DCs) (Gagliardi et al., haematopoietic lineages except for T cells and plasma 2003), in erythroid cells (Smith et al., 1994; Robinson et cells. Recently we found that Btk is involved in Toll-like al., 1998; Whyatt et al., 2000), in platelets (Quek et al., receptor signalling. Toll-like receptors play an important 1998), in hematopoietic stem cells (HSC), and role in innate immunity. They are highly expressed on multipotent progenitors (Phillips et al., 2000) as well as mast cells, macrophages and dendritic cells, which are in primary neuronal cells (Yang et al., 2004). Although essential for the recognition and consequently for the btk mutations cause primarily severe B cell defects, elimination of microbial pathogens. Therefore Btk might functions of btk-deficient or -mutated myeloid cells are play an important role for the function of also affected (see below).
    [Show full text]
  • The Bmx Tyrosine Kinase Is Activated by IL-3 and G-CSF in a PI-3K Dependent Manner
    Oncogene (2000) 19, 4151 ± 4158 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner Niklas Ekman1,6, Elena Arighi1,2,6, Iiro Rajantie1, Pipsa Saharinen3, Ari RistimaÈ ki4, Olli Silvennoinen3,5 and Kari Alitalo*,1 1Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Haartman Institute, P.O.Box 21 (Haartmaninkatu 3), 00014 University of Helsinki, Finland; 2Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy; 3Department of Virology, Haartman Institute, P.O.Box 21 (Haartmaninkatu 3), 00014 University of Helsinki, Finland; 4Department of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, 00029 Helsinki, Finland; 5Medical Biochemistry, University of Tampere, 33014 Tampere, Finland Cytoplasmic protein tyrosine kinases play crucial roles in The Tec family of PTKs consists of ®ve members: the signaling via a variety of cell surface receptors. The Bmx founder member Tec, as well as Btk, Itk/Tsk/Emt, Txk tyrosine kinase, a member of the Tec family, is and Bmx tyrosine kinases. The Tec kinases are regulated expressed in hematopoietic cells of the granulocytic and by a variety of hematopoietic receptors. For example, the monocytic lineages. Here we show that Bmx is Bruton's tyrosine kinase, Btk, is activated through the catalytically activated by interleukin-3 (IL-3) and high anity IgE receptor in mast cells, by the antigen granulocyte-colony stimulating factor (G-CSF) recep- and CD72 receptors in B-cells, as well as by interleukin-3 tors.
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]